![]() |
11th International AIDS ConferenceVancouver, British Columbia — July 7-12, 1996 |
Int Conf AIDS 1996 Jul 7-12; 11:6 (abstract no. Mo.A.152)
Hiroki B, Asakura Y, Tsuji T, Xin KQ, Sasaki S, Hamajima K, Fukushima J, Kawamoto S, Fujita K, Okuda K; Yokohama City University School of Medicine, Yokohama, Japan. Fax: 81-45-785-8438.
OBJECTIVE: To induce HIV-1-specific mucosal IgA antibody with neutralizing activity is of importance for development of HIV vaccine. Induction of secretory IgA antibody against HIV-1 was studied by oral, rectal and vaginal immunization with a new synthetic peptide vaccine candidate (VC1). Method: VC1 was composed of peptides from several third hypervariable regions (V3), a CD4 binding site (helper T cell epitope) and a Gag region of HIV-1. VC1 + cholera toxin (CT) were administered into BALB/c mice with oral, rectal and vaginal route. Fecal extract solutions or vaginal washings were collected at a week after each immunization. HIV-1-specific IgA antibody titers were determined using ELISA assay. Delayed type hypersensitivity (DTH) and cytotoxic T lymphocyte (CTL) were also examined using footpad swelling test, 51Cr release assay, respectively.
RESULTS: Oral, rectal and vaginal immunization with VC1+CT elicited high titer of HIV-1-specific secretory IgA antibody (1:27-9). Secretory IgA antibody induced by oral immunization neutralized not only laboratory strains but also primary isolates. Rectal immunization elicited fecal IgA antibody (1:29) and vaginal IgA antibody (1:27). Vaginal immunization elicited fecal IgA antibody (1:29) and vaginal IgA antibody (1:29). Rectal and vaginal administration of VC1+CT also induced HIV-1-specific DTH and CTL.
CONCLUSIONS: Mucosal immunization with VC1+CT induced secretory IgA antibody with neutralization of HIV-1 and cell-mediated immunity.
960707
MoA152
Copyright © 1996 - International AIDS Society (IAS). Reproduction of this abstract (other than one copy for personal reference) must be cleared through the IAS.